0000000000065234

AUTHOR

Emilia Bigaeva

showing 6 related works from this author

New heteronuclear gold(I)-platinum(II) complexes with cytotoxic properties: are two metals better than one?

2014

A series of mono- and heterodinuclear gold(I) and platinum(II) complexes with a new bipyridylamine-phosphine ligand have been synthesized and characterized. The X-ray structures of the ligand precursor 4-iodo-N,N-di(pyridin-2-yl)benzamide, and of one gold derivative are reported. All the complexes display antiproliferative properties in vitro in human cancer cells in the range of cisplatin or higher, which appear to correlate with compounds' uptake. Interestingly, studies of the interactions of the compounds with models of DNA indicate different mechanisms of actions with respect to cisplatin. The biological activity study of these complexes provides useful information about the interest of…

Organoplatinum CompoundsStereochemistryCell SurvivalPhosphinesPyridinesthioglucoseGOLD COMPOUNDSchemistry.chemical_elementAntineoplastic AgentsPLATINUM COMPLEXESBiochemistryRutheniumInorganic Chemistrychemistry.chemical_compoundStructure-Activity RelationshipGold CompoundsCoordination ComplexesCell Line TumormedicineHumansDNA bindingBenzamideBIOLOGICAL-PROPERTIESCell ProliferationCisplatinheteronuclear complexDERIVATIVESChemistryLigandCytotoxinsBiological activityBiological TransportDNAPYRIDINEanticancer agentRutheniumHeteronuclear moleculepolymerizationBenzamidesLIGANDSCisplatinGold complexesPlatinumOrganogold Compoundsmedicine.drugPlasmidsJournal of inorganic biochemistry
researchProduct

Dissecting the molecular antifibrotic effect of the TGF-Beta(I) receptor kinase inhibitor galunisertib in precision-cut liver slices

2016

medicine.medical_specialtyEndocrinologyHepatologyKinaseChemistryInternal medicineTGF beta signaling pathwayCancer researchmedicineGalunisertibReceptorJournal of Hepatology
researchProduct

PI3K inhibition reduces murine and human liver fibrogenesis in precisioncut liver slices

2019

Background: Liver fibrosis results from continuous inflammation and injury. Despite its high prevalence worldwide, no approved antifibrotic therapies exist. Omipalisib is a selective inhibitor of the PI3K/mTOR pathway that controls nutrient metabolism, growth and proliferation. It has shown antifibrotic properties in vitro. While clinical trials for idiopathic pulmonary fibrosis have been initiated, an in-depth preclinical evaluation is lacking. We evaluated omipalisib's effects on fibrogenesis using the ex vivo model of murine and human precision-cut tissue slices (PCTS).Methods: Murine and human liver and jejunum PCTS were incubated with omipalisib up to 10 mu M for 48 h. PI3K pathway act…

0301 basic medicineLiver CirrhosisMalePrecision-cut tissue slicesPROGRESSIONPharmacologyBILIARYBiochemistryPI3KGSK2126458JejunumMicePhosphatidylinositol 3-Kinases0302 clinical medicineAdenosine TriphosphateFibrosisFIBROSIShealth care economics and organizationsPhosphoinositide-3 Kinase InhibitorsSulfonamidesPyridazinesmedicine.anatomical_structureJejunumTARGET030220 oncology & carcinogenesisToxicityQuinolinesPhosphorylationmedicine.symptomATP Binding Cassette Transporter Subfamily BLiver fibrosisEARLY-ONSETInflammation03 medical and health sciencesmedicineAnimalsHumansOmipalisibProtein kinase BPI3K/AKT/mTOR pathwayPharmacologybusiness.industryCUT LIVERmedicine.diseaseMice Inbred C57BLMODEL030104 developmental biologybusinessMATRIXEx vivoBiochemical Pharmacology
researchProduct

Investigating fibrosis and inflammation in an ex vivo NASH murine model.

2020

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease, characterized by excess fat accumulation (steatosis). Nonalcoholic steatohepatitis (NASH) develops in 15–20% of NAFLD patients and frequently progresses to liver fibrosis and cirrhosis. We aimed to develop an ex vivo model of inflammation and fibrosis in steatotic murine precision-cut liver slices (PCLS). NASH was induced in C57Bl/6 mice on an amylin and choline-deficient l-amino acid-defined (CDAA) diet. PCLS were prepared from steatohepatitic (sPCLS) and control (cPCLS) livers and cultured for 48 h with LPS, TGFβ1, or elafibranor. Additionally, C57Bl/6 mice were placed on CDAA diet for 12 wk to receive elafibranor…

0301 basic medicineLipopolysaccharidesLiver CirrhosisMalePhysiologyHEPATOCYTESLiver diseaseMice0302 clinical medicineChalconesFibrosisNon-alcoholic Fatty Liver DiseaseNonalcoholic fatty liver diseaseCells CulturedINSULIN-RESISTANCEGastroenterologyElafibranorTGF-BETALiver030211 gastroenterology & hepatologyCHOLINE-DEFICIENT DIETEXPRESSIONmedicine.medical_specialtyEARLY-ONSETIn Vitro TechniquesCollagen Type IProinflammatory cytokineTransforming Growth Factor beta103 medical and health sciencesIn vivoPhysiology (medical)Internal medicinemedicineAnimalsHEPATIC STEATOSISFATTY LIVER-DISEASEInflammationPRECISION-CUT LIVERHepatologybusiness.industrymedicine.diseaseLipid MetabolismDietMice Inbred C57BLDisease Models Animal030104 developmental biologyEndocrinologyPROLIFERATOR-ACTIVATED RECEPTORSSteatosisPropionatesbusinessTranscriptomeEx vivoAmerican journal of physiology. Gastrointestinal and liver physiology
researchProduct

Exploring organ-specific features of fibrogenesis using murine precision-cut tissue slices

2019

Fibrosis is the hallmark of pathologic tissue remodelling in most chronic diseases. Despite advances in our understanding of the mechanisms of fibrosis, it remains uncured. Fibrogenic processes share conserved core cellular and molecular pathways across organs. In this study, we aimed to elucidate shared and organ-specific features of fibrosis using murine precision-cut tissue slices (PCTS) prepared from small intestine, liver and kidneys. PCTS displayed substantial differences in their baseline gene expression profiles: 70% of the extracellular matrix (ECM)-related genes were differentially expressed across the organs. Culture for 48 h induced significant changes in ECM regulation and trig…

Liver CirrhosisEXPRESSION0301 basic medicineINHIBITOR LY2157299 MONOHYDRATEPROTEINPrecision-cut tissue slicesSmad2 ProteinLIVER FIBROSISBiologyKidneyMECHANISMSSMAD2ACTIVATIONPATHWAYExtracellular matrixMiceTGFβ03 medical and health sciences0302 clinical medicineTransforming Growth Factor betaTGF betaFibrosisGene expressionTGF beta signaling pathwaymedicineAnimalsGalunisertibProtein Kinase InhibitorsMolecular BiologyMOLECULAR CHAPERONEGROWTH-FACTOR-BETAKinaseTGF-BETAExtracellular matrixmedicine.diseaseFibrosisPathophysiologyCell biologyMice Inbred C57BL030104 developmental biologyLiver030220 oncology & carcinogenesisQuinolinesPyrazolesMolecular MedicineCollagenHomeostasisSignal TransductionBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
researchProduct

Evaluating the antifibrotic potency of galunisertib in a human ex vivo model of liver fibrosis

2017

Background and Purpose Liver fibrosis is a major cause of liver-related mortality and, so far, no effective antifibrotic drug is available. Galunisertib, a TGF-β receptor type I kinase inhibitor, is a potential candidate for the treatment of liver fibrosis. Here, we evaluated the potency of galunisertib in a human ex vivo model of liver fibrosis. Experimental Approach Antifibrotic potency and associated mechanisms were studied ex vivo, using both healthy and cirrhotic human precision-cut liver slices. Fibrosis-related parameters, both transcriptional and translational level, were assessed after treatment with galunisertib. Key Results Galunisertib showed a prominent antifibrotic potency. Ph…

0301 basic medicinePharmacologymedicine.medical_specialtyPharmacologyBiologyExtracellular matrix03 medical and health sciences030104 developmental biology0302 clinical medicineEndocrinologyMechanism of action030220 oncology & carcinogenesisInternal medicinemedicineHepatic stellate cellGalunisertibPotencymedicine.symptomSignal transductionReceptorEx vivoBritish Journal of Pharmacology
researchProduct